Form 4: Trevi Therapeutics Executive Acquires Stock Options

James V. Cassella, Chief Development Officer of Trevi Therapeutics, Inc., was granted stock options for 257,500 shares of common stock on February 18, 2025.

Summary

• James V. Cassella, the Chief Development Officer of Trevi Therapeutics, Inc. (TRVI), filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Cassella on February 18, 2025.
• The options give Cassella the right to buy 257,500 shares of Trevi Therapeutics' common stock at an exercise price of $4.22 per share.
• The options vest as to 25% of the shares on February 18, 2026, and the remaining 75% vest in equal monthly installments through February 18, 2029.
• Following the transaction, Cassella directly owns options for 257,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine executive compensation disclosure. The grant of options can be seen as a positive incentive, but it's not a major event.

Positives

• The granting of stock options to a key executive like the Chief Development Officer can be seen as an incentive to align their interests with the long-term success of the company.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedule encourages long-term commitment to the company's goals.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The vesting schedule of these options is fairly standard, with vesting occurring over a period of several years to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the Chief Development Officer, potentially benefiting the company's long-term prospects.

Key Dates

Keywords

Form 4, Stock Options, Trevi Therapeutics, TRVI, James V. Cassella, Chief Development Officer, Beneficial Ownership, SEC Filing